Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Novel therapeutic option for orbital atypical lymphoid hyperplasia

Date

Authors

Talaulikar, Dipti

Tridgell, David

Leong, David C S

Cherian, Maya

Sunderland, Ken

Dahlstrom, Jane

Publisher

Blackwell Science Asia

Abstract

Ocular lymphoid tumours represent a spectrum of lymphoproliferative disease and can be subdivided into benign or reactive lymphoid hyperplasia, indeterminate or atypical lymphoid proliferations and malignant lymphoma. Treatment options include a wait and

Keywords

Keywords: rituximab; adult; article; B lymphocyte; case report; clinical decision making; exophthalmos; female; flow cytometry; follow up; human; immunoglobulin heavy chain gene; immunophenotyping; lymphoid hyperplasia; nuclear magnetic resonance imaging; orbit dis B-lymphocyte; Haematopathology; Lymphoproliferative disorder; Orbital; Pathology of lymphoid lesion

URI

http://hdl.handle.net/1885/64872

Collections

ANU Research Publications

Source

Clinical and Experimental Ophthalmology

Type

Journal article

DOI

10.1111/j.1442-9071.2010.02378.x

Restricted until

2037-12-31

Downloads

File

Description

01_Talaulikar_Novel_therapeutic_option_for_2010.pdf (847.18 KB)

abcd